<DOC>
	<DOCNO>NCT02295722</DOCNO>
	<brief_summary>Objective study : To evaluate safety efficacy infusional gemcitabine prior HDM ( high-dose melphalan ) HDCT ( High Dose Chemotherapy ) follow autologous stem cell transplantation patient relapsed/refractory lymphoma .</brief_summary>
	<brief_title>GEMHDM2014 : Gem-HDM HDT ASCT Relapsed/ Refractory Lymphoma</brief_title>
	<detailed_description>High-dose chemotherapy autologous stem cell transplantation current standard care patient chemosensitive relapse Hodgkin 's lymphoma aggressive non-Hodgkin 's lymphoma , establish effective therapy patient relapse follicular lymphoma . Disease relapse remain major problem , occur 50 % patient , particularly patient primary refractory disease high-risk feature . The addition gemcitabine single-agent melphalan high-dose conditioning regimen present promise combination may lead improvement EFS ( Event free survival ) . If trial give encouraging result , may lead phase III trial evaluate treatment strategy . Drug exposure would AUC ( area curve ) clinical factor would thing like obesity , renal function , disease characteristic . We would look safety outcome - i.e . adverse event measure safety tolerability . The adverse event would non-hematological toxicity ( ) whether related AUC . AUC relationship PFS ( progression free survival ) also important ( want know need adjust dose improve PFS ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Ability provide write informed consent 2 . Age 18 year 3 . Relapsed/refractory lymphoma least 1 prior chemotherapy treatment : 1 . Hodgkin 's lymphoma 2 . Aggressive nonHodgkin 's lymphoma 3 . Follicular lymphoma 4 . Chemosensitive disease time transplantation ( i.e . partial response well salvage chemotherapy ) 5 . ECOG ( Eastern Cooperative Oncology Group ) performance 02 6 . Adequate organ function : 1 . Cardiac : LVEF ( leave ventricular ejection fraction ) &gt; 40 % 2 . Pulmonary : FEV1 ( forced expiratory volume one second ) DLCO ( diffuse capacity lung carbon monoxide ) &gt; 60 % predict 3 . Renal : creatinine &lt; 150 Âµmol/L unless cause ureteric obstruction lymphoma 4 . Liver : No evidence cirrhosis . ALT ( Alanine Aminotransferase ) bilirubin &lt; 2x upper limit normal unless cause biliary tract obstruction lymphoma 1 . Clinically significant active infection 2 . Active secondary central nervous system disease 3 . Other serious comorbid illness would compromise study participation . 4 . Pregnant lactating female 5 . Prior HDCT/ASCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>eligible high-dose therapy stem cell transplantation</keyword>
</DOC>